impact factor, citescore
logo
 

Review

 

Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica


, ,

 

CER4147
2010 Vol.28, N°5 ,Suppl.61
PI 0172, PF 0177
Review

Free to view
(click on article PDF icon to read the article)

PMID: 21044455 [PubMed]

Received: 09/09/2010
Accepted : 09/09/2010
In Press: 28/10/2010
Published: 28/10/2010

Abstract

In large vessel vasculitis, including giant cell arteritis and Takayasu arteritis, as well as in polymyalgia rheumatica, glucocorticoid therapy is the treatment of choice. However, there are two situations/questions for additional immunosuppressive therapies in these diseases: (i) therapy resistance to glucocorticoid mono-therapy; (ii) situations which call for sparing of glucocorticoids such as in complications of glucocorticoid therapy. This review summarises the current scientific debate on the effects of methotrexate in these diseases. Methotrexate at 10–15 mg/week appears to have a modest and delayed effect in GCA and PMR in reducing relapse rate and lowering the cumulative dose of glucocorticoid therapy. However, superiority of combination therapy in reducing the incidence of glucocorticoidrelated complications has not been shown yet. The effects of higher doses and long-time effects as well as the efficacy in patients with glucocorticoid-resistance and complications are unclear. Methotrexate may thus be considered as adjunctive therapy to glucocorticoid therapy in glucocorticoid-resistance or complications. Further attempts should be made for a better identification of patients with glucocorticoid-refractory courses and a more precise formulation of guidelines on indication, optimal dosing and duration.

Rheumatology Article